Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Prostate Pub Date : 2024-09-01 Epub Date: 2024-05-12 DOI:10.1002/pros.24745

Hugo Barriere, Kévin Kaulanjan, Gautier Stempfer, Philippe Mollard, Mélanie Laguerre, Cédric Senechal, Gilles Gourtaud, Virginie Roux, Yvanne Sadreux, Pascal Blanchet, Laurent Brureau

{"title":"Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.","authors":"Hugo Barriere, Kévin Kaulanjan, Gautier Stempfer, Philippe Mollard, Mélanie Laguerre, Cédric Senechal, Gilles Gourtaud, Virginie Roux, Yvanne Sadreux, Pascal Blanchet, Laurent Brureau","doi":"10.1002/pros.24745","DOIUrl":null,"url":null,"abstract":"Introduction: Early salvage radiotherapy is indicated for patients with biochemical recurrence after radical prostatectomy. However, for various reasons, certain patients do not benefit from this treatment (OBS) or only at a late stage (LSR). There are few studies on this subject and none on a \"high-risk\" population, such as patients of African descent. Our objective was to estimate the metastasis-free (MFS) and overall survival (OS) of patients who did not receive salvage radiotherapy, and to identify risk factors of disease progression.Patients and methods: This was a single-center retrospective study that included 154 patients, 99 in the OBS group and 55 in the LSR group. All were treated by total prostatectomy for localized prostate cancer between January 2000 and December 2020 and none received early salvage radiotherapy after biochemical recurrence.Results: Baseline characteristics were similar between groups, except for the time to biochemical recurrence. The median follow-up was 10.0 and 11.8 years for the OBS and LSR groups, respectively. The median time from surgery to LSR was 5.1 years. The two groups did not show a significant difference in MFS: 90.6% at 10 years for the OBS group and 93.3% for the LSR group. The median MFS was 19.8 and 19.6 years for the OBS and LSR groups respectively. OS for the OBS group was significantly higher than that for the LSR group (HR: 2.14 [1.07-4.29]; p = 0.03), with 10-year OS of 95.9% for the OBS group and 76.1% for the LSR group. Median OS was 16 and 15.6 years for the OBS and LSR groups, respectively.Conclusion: In this study, we observed satisfactory metastasis-free and OS rates relative to those reported in the scientific literature. The challenge is not to question the benefit of early salvage radiotherapy, but to improve the identification of patients at risk of progression through the development of molecular and genomic tests for more highly personalized medicine.","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1112-1118"},"PeriodicalIF":2.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24745","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Early salvage radiotherapy is indicated for patients with biochemical recurrence after radical prostatectomy. However, for various reasons, certain patients do not benefit from this treatment (OBS) or only at a late stage (LSR). There are few studies on this subject and none on a "high-risk" population, such as patients of African descent. Our objective was to estimate the metastasis-free (MFS) and overall survival (OS) of patients who did not receive salvage radiotherapy, and to identify risk factors of disease progression.

Patients and methods: This was a single-center retrospective study that included 154 patients, 99 in the OBS group and 55 in the LSR group. All were treated by total prostatectomy for localized prostate cancer between January 2000 and December 2020 and none received early salvage radiotherapy after biochemical recurrence.

Results: Baseline characteristics were similar between groups, except for the time to biochemical recurrence. The median follow-up was 10.0 and 11.8 years for the OBS and LSR groups, respectively. The median time from surgery to LSR was 5.1 years. The two groups did not show a significant difference in MFS: 90.6% at 10 years for the OBS group and 93.3% for the LSR group. The median MFS was 19.8 and 19.6 years for the OBS and LSR groups respectively. OS for the OBS group was significantly higher than that for the LSR group (HR: 2.14 [1.07-4.29]; p = 0.03), with 10-year OS of 95.9% for the OBS group and 76.1% for the LSR group. Median OS was 16 and 15.6 years for the OBS and LSR groups, respectively.

Conclusion: In this study, we observed satisfactory metastasis-free and OS rates relative to those reported in the scientific literature. The challenge is not to question the benefit of early salvage radiotherapy, but to improve the identification of patients at risk of progression through the development of molecular and genomic tests for more highly personalized medicine.

查看原文本刊更多论文

根治性前列腺切除术后生化复发的非洲裔加勒比患者的总生存率和无转移生存率。

前言：早期挽救性放疗适用于根治性前列腺切除术后出现生化复发的患者。然而，由于种种原因，某些患者并不能从这种治疗中获益（OBS），或者只能在晚期获益（LSR）。关于这个问题的研究很少，而且没有针对 "高危 "人群（如非洲裔患者）的研究。我们的目标是估算未接受挽救性放疗患者的无转移生存期（MFS）和总生存期（OS），并确定疾病进展的风险因素：这是一项单中心回顾性研究，共纳入154例患者，其中OBS组99例，LSR组55例。所有患者均在2000年1月至2020年12月期间接受了局部前列腺癌全前列腺切除术，没有人在生化复发后接受早期挽救性放疗：结果：除生化复发时间外，两组的基线特征相似。OBS组和LSR组的中位随访时间分别为10.0年和11.8年。从手术到LSR的中位时间为5.1年。两组的 MFS 没有明显差异：OBS 组 10 年的 MFS 为 90.6%，LSR 组为 93.3%。OBS组和LSR组的中位MFS分别为19.8年和19.6年。OBS组的OS明显高于LSR组（HR：2.14 [1.07-4.29]; p = 0.03），OBS组的10年OS为95.9%，LSR组为76.1%。OBS组和LSR组的中位OS分别为16年和15.6年：在这项研究中，我们观察到了令人满意的无转移率和OS率，与科学文献中报道的结果相当。我们面临的挑战不是质疑早期抢救性放疗的益处，而是通过开发分子和基因组检测技术，改善对有进展风险的患者的识别，从而实现更高度的个性化医疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate 医学-泌尿学与肾脏学

CiteScore

5.10

自引率

3.60%

发文量

180

审稿时长

1.5 months

期刊介绍： The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.